文献速递冠心病

药物涂层球囊与药物洗脱支架治疗小血管冠心病的个体患者数据荟萃分析:ANDROMEDA研究

Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study.
PubMed 文献 · Eur Heart J · 2025-01-01

ANDROMEDA研究是一项个体患者数据荟萃分析,纳入三项随机试验共1154例患者1360处病变,比较紫杉醇涂层球囊(PCB)与药物洗脱支架(DES)治疗新发小血管冠状动脉疾病(SV-CAD)的3年临床结局。结果显示PCB组主要不良心脏事件(MACE)风险低于DES组(HR 0.67,95%CI 0.47-0.96),靶病变失败(TLF)无显著差异。

要点

  • PCB组3年MACE风险显著低于DES组(HR 0.67,95%CI 0.47-0.96)。
  • PCB与DES的3年TLF无显著差异。
  • 与第二代DES比较,PCB的3年TLF无显著差异(HR 1.03,95%CI 0.70-1.50)。

核心结论

  • 对于接受PCI的新发SV-CAD患者,PCB血管成形术与DES植入相比,3年随访时MACE风险降低,TLF无显著差异。
  • 将比较组限制为第二代DES不改变主要结论。

研究设计与样本

  • ANDROMEDA研究为协作性、研究者发起的个体患者数据荟萃分析,比较PCB与DES治疗新发SV-CAD的3年临床结局。
  • 检索PubMed、Scopus、ScienceDirect和Web of Science(2010年5月至2024年6月),纳入随机分配、SV-CAD、PCB或DES治疗、临床随访至少36个月的试验。
  • 合并三项随机试验的个体患者数据,共1154例患者和1360处病变。
  • 主要终点为MACE,共同主要终点为TLF。
  • 方案在PROSPERO注册(CRD42023479035)。

主要发现

  • 3年时,PCB组MACE风险低于DES组(HR 0.67,95%CI 0.47-0.96),归因于心肌梗死和靶血管血运重建风险降低。
  • 多变量调整后该获益持续(HR 0.75,95%CI 0.58-0.96),但两阶段分析未达统计学显著性(HR 0.67,95%CI 0.43-1.04)。
  • 标志分析显示两组间MACE风险随时间保持一致。
  • 3年时TLF在PCB与DES组间无显著差异。
  • 敏感性分析纳入第四项试验重建的时间-事件信息(1384例患者和1590处病变),TLF结果一致(HR 0.87,95%CI 0.63-1.20)。

临床怎么用

  • 对于新发SV-CAD的PCI患者,PCB血管成形术可作为DES的替代选择,与3年MACE风险降低相关。
  • PCB与DES的3年TLF无显著差异,支持PCB在SV-CAD中的应用。

局限性

  • 三项随机试验存在样本量限制。
  • 两阶段分析中MACE获益未达统计学显著性(HR 0.67,95%CI 0.43-1.04)。
  • 需要更大样本、当代器械和更长随访的试验来确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: In randomized clinical trials of patients undergoing percutaneous coronary intervention (PCI) for de novo small-vessel coronary artery disease (SV-CAD), paclitaxel-coated balloon (PCB) angioplasty showed mid-term angiographic or clinical non-inferiority to drug-eluting stent (DES) implantation. Nevertheless, these trials have sample size limitations, and the relative safety and efficacy beyond the first year remain uncertain. METHODS: The ANDROMEDA study was a collaborative, investigator-initiated, individual patient data meta-analysis comparing 3 year clinical outcomes between PCB angioplasty and DES implantation for the treatment of de novo SV-CAD. Multiple electronic databases (PubMed, Scopus, ScienceDirect, and Web of Science) were searched from May 2010 to June 2024 to identify eligible trials. All the following eligibility criteria were required: (i) random allocations of treatments; (ii) patients with SV-CAD; (iii) treatment with PCB or DES; and (iv) clinical follow-up of at least 36 months. The primary and co-primary endpoints were major adverse cardiac events (MACE) and target lesion failure (TLF), respectively. The protocol was registered with PROSPERO (CRD42023479035). RESULTS: Individual patient data from three randomized trials, including a total of 1154 patients and 1360 lesions, were combined. At 3 years, PCB was associated with a lower risk of MACE compared with DES [hazard ratio (HR) 0.67, 95% confidence interval (CI) 0.47-0.96], due to a lower risk of myocardial infarction and target vessel revascularization. This benefit persisted after multivariable adjustment (HR 0.75, 95% CI 0.58-0.96), but did not reach statistical significance in the two-stage analysis (HR 0.67, 95% CI 0.43-1.04). At the landmark analysis, the risk of MACE between groups was consistent over time. At 3 years, TLF was not significantly different between PCB and DES groups. Reconstructed time-to-event information from a fourth trial was included in a sensitivity analysis (1384 patients and 1590 lesions), showing consistent results in terms of TLF (HR 0.87, 95% CI 0.63-1.20). The comparison between PCB and second-generation DES did not reveal significant differences in 3 year TLF (HR 1.03, 95% CI 0.70-1.50). CONCLUSIONS: In patients undergoing PCI for de novo SV-CAD, PCB angioplasty is associated with a reduction in MACE and a non-significant difference in TLF at 3 year follow-up compared with DES implantation. The restriction of the comparator group to second-generation DES does not alter the main conclusions. Larger trials comparing contemporary devices at a more prolonged follow-up are warranted to confirm these findings.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Fezzi S, Giacoppo D, Fahrni G, et al. Individual patient data meta-analysis of paclitaxel-coated balloons vs. drug-eluting stents for small-vessel coronary artery disease: the ANDROMEDA study. Eur Heart J. 2025. PMID: 39981922. doi:10.1093/eurheartj/ehaf002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。